Cell Signaling Technology, Inc. Announces the Launch of SignalSilence® siRNA Kits for the Study of Signal Transduction
BEVERLY, MA - November 17, 2003 - Cell Signaling Technology, Inc. (CST) announced the launch of validated SignalSilence® siRNA Kits for signal transduction research. These kits allow the researcher to specifically inhibit and monitor protein expression. The kit utilizes RNA interference, a method in which gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell.
Unlike other siRNA products on the market SignalSilence® siRNA kits have been rigorously tested in-house and assayed at the level of protein rather than mRNA expression. The kits include specific siRNA, a target-specific antibody to confirm reduction of protein expression, and a non-target antibody to control for loading and monitor specificity of the targeted siRNA. Additionally, a fluorescein-labeled non-targeted siRNA control allows the user to monitor transfection efficiency and siRNA specificity. The kit also contains a transfection reagent from Mirus Corp. (www.mirusbio.com) optimized for efficient siRNA delivery in mammalian cells.
“CST’s core strength has always been the development and validation in house of innovative and high quality products for signal transduction research,” said Michael Melnick, Vice President of Business Development, CST. “Our customers have asked for a consistent source of products that work, in particular siRNA that have been validated at the level of protein expression. SignalSilence® allows the user to consistently inhibit protein expression, and monitor that inhibition using high-quality CST antibodies to the target as well as phospho-specific antibodies to downstream signaling events.”